A review of estrogen receptor/androgen receptor genomics in male breast cancer

Male breast cancer: Looking for better prognostic subgroups

(2016) Miguel Henriques Abreu et al.   BREAST

Prognostic factors in male breast cancer: a population-based study

(2016) José Pablo Leone et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Genomic Landscape of Male Breast Cancers

(2016) Salvatore Piscuoglio et al.   CLINICAL CANCER RESEARCH

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

(2016) W. Li et al.   CLINICAL CANCER RESEARCH

The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer

(2016) Sherry Zhao et al.   Expert Review of Anticancer Therapy

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status

(2016) He-Sheng Jiang et al.   Oncotarget

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years

(2016) Ji Hyung Hong et al.   Cancer Research and Treatment

Androgen receptor and antiandrogen therapy in male breast cancer

(2015) Luigi Di Lauro et al.   CANCER LETTERS

Androgen receptor profiling predicts prostate cancer outcome

(2015) Suzan Stelloo et al.   EMBO Molecular Medicine

Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer

(2015) Hedde D. Biesma et al.   GENES CHROMOSOMES & CANCER

Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes

(2015) Ida Johansson et al.   Molecular Oncology

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

(2015) Zhenfei Li et al.   NATURE

Androgen receptor in male breast cancer

(2015) Beata Sas-Korczynska et al.   POLISH JOURNAL OF PATHOLOGY

Targeting the Androgen Receptor in Breast Cancer

(2015) KeeMing Chia et al.   Current Oncology Reports

The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping

(2014) Sotiris Lakis et al.   BREAST

Molecular profiling of male breast cancer – Lost in translation?

(2014) Ida Johansson et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Expression of Androgen Receptor and Its Association With Estrogen Receptor and Androgen Receptor Downstream Proteins in Normal/Benign Breast Luminal Epithelium

(2014) Xi Wang et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Male breast cancer: genetics, epigenetics, and ethical aspects

(2013) P. Rizzolo et al.   ANNALS OF ONCOLOGY

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples

(2013) Wilbert Zwart et al.   BMC GENOMICS

Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer

(2013) M. P. H. M. Jansen et al.   CANCER RESEARCH

An update on male breast cancer and future directions for research and treatment

(2013) Berta Sousa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo

(2013) Aleksandra M. Ochnik et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Ex vivo culture of human prostate tissue and drug development

(2013) Margaret M. Centenera et al.   Nature Reviews Urology

The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer

(2013) Ida Johansson et al.   PLoS One

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors

(2012) M. M. Centenera et al.   CLINICAL CANCER RESEARCH

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers

(2012) Kern Rei Chng et al.   EMBO JOURNAL

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

(2012) V. Theodorou et al.   GENOME RESEARCH

High proliferation is associated with inferior outcome in male breast cancer patients

(2012) Cecilia Nilsson et al.   MODERN PATHOLOGY

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

(2012) Caryn S. Ross-Innes et al.   NATURE

An integrated encyclopedia of DNA elements in the human genome

(2012)   NATURE

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

(2011) Abeer M. Shaaban et al.   BREAST CANCER RESEARCH AND TREATMENT

Male Breast Cancer: Management and Follow-up Recommendations

(2011) John V. Kiluk et al.   Breast Journal

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

(2011) R. Hu et al.   CLINICAL CANCER RESEARCH

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1

(2011) Jessica L L Robinson et al.   EMBO JOURNAL

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

(2011) Meredith M Regan et al.   LANCET ONCOLOGY

Chromatin binding by the androgen receptor in prostate cancer

(2011) Harri Itkonen et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

(2010) Ida Johansson et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

(2010) E Mrozek et al.   CANCER RESEARCH

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

(2010) Larissa A. Korde et al.   JOURNAL OF CLINICAL ONCOLOGY

Aromatase inhibition in male breast cancer patients: biological and clinical implications

(2009) J. Doyen et al.   ANNALS OF ONCOLOGY

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

(2009) Qianben Wang et al.   CELL

Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer

(2009) William F. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors

(2008) Elisa J. Cops et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY